Lebanon, NH: Celdara Medical, LLC today announced Dr. Jonathan Heller as its first Entrepreneur in Residence (EIR). Celdara Medical is developing a diverse portfolio of preclinical therapeutic assets, platforms, and companies. Heller is primarily responsible for advancing one of Celdara’s lead therapeutic programs to spin-out or exit.
“Celdara’s pipeline is robust and diverse, and so an Entrepreneur in Residence is a natural way to increase the pace of bringing innovative new medicines to patients,” remarked Dr. Jake Reder, co-founder and Chief Executive Officer of Celdara Medical. “Jonathan is ideally suited to be Celdara’s first EIR. His experience bringing multiple therapies to clinic, in big pharma and in his own companies, is already adding value to our portfolio. Most importantly, his integrity and patient focus align perfectly with our company values. I look forward to a highly productive and enjoyable working relationship with Jonathan.”
Heller has spent over 20 years building biotechnology company pipelines by leading drug and business development efforts at companies like BioMarin, Synageva, and Pfizer. Among his accomplishments is leading the preclinical development of BioMarin’s Brineura and Vosoritide, the first ever approved treatments for late infantile neuronal ceroid lipofuscinosis and achondroplasia. He also led the initial development of Valoctocogene roxaparvovec, the first approved gene therapy for Hemophilia type A. “I am honored to join Celdara Medical, a company designed from the start to help ensure patients in need will benefit from academic innovations. I look forward to building upon Celdara’s commitment to patient health and accelerating one or more of their fruitful collaborations with inventors”, said Jonathan. Heller earned an MBA from The University of California at Berkeley, a PhD in biology from The Johns Hopkins University, and a BA in Biochemistry and Molecular Biology from Reed College.
About Celdara Medical, LLC
Celdara Medical was founded by Drs. Jake Reder and Michael Fanger in 2008 and is headquartered at the Dartmouth Regional Technology Center (DRTC) in Lebanon, NH. Celdara Medical builds academic and early-stage innovations into high-potential medical companies, identifying discoveries of exceptional value at the earliest stages and moving them toward the market. Celdara Medical partners with inventors and their institutions, providing the developmental, financial, and business acumen required to bridge discovery and profitability. With robust funding options, a diverse and high impact Programmatic pipeline, and partnerships with world-class academic institutions and industry leaders, Celdara Medical navigates all aspects of a complex industry, accelerating science to improve human health.